| 
 | |||||
|   | 
| 
 | 

Digital medical services platform Teladoc Health (NYSE:TDOC) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 2.2% year on year to $626.4 million. The company expects next quarter’s revenue to be around $637 million, close to analysts’ estimates. Its GAAP loss of $0.28 per share was 9.2% below analysts’ consensus estimates.
Is now the time to buy TDOC? Find out in our full research report (it’s free for active Edge members).
Teladoc’s third quarter results were met with a negative market reaction, as revenue landed in line with Wall Street’s expectations but continued to decline year-over-year. Management attributed the performance to ongoing challenges in its U.S. direct-to-consumer mental health segment and a mix shift towards visit-based revenues. CEO Charles Divita highlighted the company’s efforts to enhance product offerings and drive greater engagement across its integrated care and mental health platforms. He stated, "We know that we have important work ahead of us," acknowledging that pressures on affordability and rising costs remain substantial across the healthcare landscape.
Looking ahead, Teladoc’s guidance is shaped by a strategic pivot toward insurance-based mental health offerings and continued investment in product innovation. Management expects the ramp-up of the BetterHelp insurance rollout and international expansion to gradually offset U.S. cash pay headwinds. CFO Mala Murthy cautioned that, while early signs of the insurance rollout are promising, "the economics you see and the margins you see today are almost entirely cash pay" and improvements will take time. The company is also focused on cost discipline and operational streamlining as it works to restore profitability.
Management attributed the quarter’s results to a combination of innovation in integrated care, ongoing challenges in U.S. mental health, and a deliberate focus on operational efficiency.
Management’s outlook is anchored by the transition to insurance-based mental health, ongoing product enhancements, and international expansion, but acknowledges persistent margin pressures and competitive headwinds.
In the coming quarters, our team will be monitoring (1) the pace and effectiveness of BetterHelp’s insurance rollout and its impact on user growth, (2) adoption and revenue contribution from new integrated care products and chronic care interventions, and (3) continued international expansion, particularly in Australia and other key markets. Progress on cost containment and further product innovation will also be crucial for Teladoc’s profitability trajectory.
Teladoc currently trades at $7.95, down from $8.22 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free for active Edge members).
When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
| 2 hours | |
| 5 hours | |
| 6 hours | |
| 12 hours | |
| 12 hours | |
| Oct-29 | |
| Oct-29 | |
| Oct-29 | |
| Oct-29 | |
| Oct-29 | |
| Oct-28 | |
| Oct-28 | |
| Oct-27 | |
| Oct-27 | |
| Oct-24 | 
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite